An Official Website of the United States Government
Search
Company: NUTRASORB, LLC Agency/Program/Year/Phase: USDA / SBIR / 2012 / 2
Abstract: This application directly addresses Agriculturally-related Manufacturing Technology cross-cutting priority for USDA. The Nutrasorb technology enables manufacture of a new generation of science-based, efficacious, shelf-stable, and tasty anti-diabetic / anti-obesity functional… more
Company: VIDASYM, INC. Agency/Program/Year/Phase: HHS / STTR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Diabetes is by far the leading cause of CKD (diabetic nephropathy), accounting for 44% of new cases of dialysis (in 2005). Current treatments… more
Company: ION CHANNEL INNOVATIONS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … the hSlo gene splice variant, called hMaxiK, which codes for the pore forming subunit of the large conductance potassium channel. Prior studies by ICI have shown that hMaxiK improves urogenital pathophysiology in rodent and nonhuman primate models of aging, diabetes and… more
Company: NEURO DEVICES, INC. Agency/Program/Year/Phase: HHS / STTR / 2012 / 1
Abstract: …n in less than 3 minutes. This sensitivity exceeds that of current tests and allows early detection of nerve damage. In Phase I we will build a new prototype Bumps device and show feasibility by measuring tactile thresholds of small cohorts of patients with diabetes (because of… more
Company: GENALYTE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Genalyte will demonstrate the feasibility of our bio-sensing instrument platform for rapid sensitive high- throughput and low cost multiplexed panels to identify and monitor immune status for Type 1 Diabetes (T1D) auto-antibodies. The key to… more
Company: GLYCOSCIENTIFIC, L.L.C. Agency/Program/Year/Phase: HHS / STTR / 2012 / 1
Abstract: … and fluctuates in response to cellular stimuli. O-GlcNAc often competes with protein phosphorylation, and these two modifications have extensive crosstalk in the regulation of signaling, transcription, and the functions of oncogenes and tumor suppressors. Diabetes,… more
Company: EMBEDRF, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Type 1 diabetes often leads to short-term and long-term complications which impair quality of life. Many research groups, including ours, are developing an artificial endocrine pancreas (AP), which combines continuous glucose sensing with… more
Company: Canton Biotechnologies Inc Agency/Program/Year/Phase: DOD / SBIR / 2012 / 1
Abstract: … dermal elements including vasculature, skin appendages such as hair follicles, as well as epithelial and dermal differentiation. The ultimate product for development will be a gel for treating burns and other wounds such as decubitus ulcers, venous ulcers and diabetic… more
Company: Caldera Pharmaceuticals Inc. Agency/Program/Year/Phase: DOD / SBIR / 2012 / 1
Abstract: … are hexavalent Cr (Cr+6, which is associated with industrial exposure and toxicity) and trivalent Cr (Cr+3, which is stable and a biologically active form). Cr+3 is an essential nutrient for humans and shortages may cause heart conditions and metabolic disruptions or diabetes;… more
Company: Eyenuk LLC Agency/Program/Year/Phase: HHS / STTR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): In this STTR project, we present EyeMark, a set of tools for automated computation of biomarkers for diabetic retinopathy using retinal image photographs. Specifically, we will develop tools for computation of… more
Company: Eyenuk LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Abstract In this small business innovations research (SBIR) project, we present aiArt: Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine applications. aiArt (pronounced eye-art), with its automated image… more
Company: CHRYSALIS BIOTHERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … when radiation is combined with injury (RCI). Agents to mitigate effects of radiation and RCI must therefore be developed and stockpiledfor emergency use. We proposed that TP508 (rousalatide acetate), a novel peptide drug currently in clinical trials for healing diabetic… more
Company: OPHYSIO, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … cellbiology. This is a rapidly expanding market that includes clinical uses (islet transplantation), active in vitro research on adult/fetal islets of several species, and pre-clinicl stem cell research with the potential to revolutionize the treatment of diabetes… more
Company: AUTOMATED MEDICAL DIAGNOSTICS, LLC Agency/Program/Year/Phase: USDA / SBIR / 2012 / 1
Abstract: … are not met by current healthcare delivery models. As an emerging technology, telemedicine is an efficient, cost-effective way to deliver healthcare services to rural, health disparity communities. Hubble Telemedical currently provides remote management of diabetic … more
Company: Liberating Technologies, Inc. Agency/Program/Year/Phase: ED / SBIR / 2012 / 1
Abstract: … between the socket and skin. The volume changes may be due to inactivity, weight gain or loss, medications, vascular conditions, or other medical complications. Additionally, the residual limb may have reduced sensation due to neuropathy related to diabetes. This project… more
Company: BIOPANCREATE, INC. Agency/Program/Year/Phase: HHS / STTR / 2012 / 1
Abstract: …vided by applicant): The product that will result from the proposed SBIR program, a consortium collaboration between BioPancreate (a small business) and Cornell University, will be an orally-administered insulin-replacement therapy for bothtype-1 and type-2 diabetes mellitus,… more
Company: AVALANCHE BIOTECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … of this proposal is to examine the efficacy of novel adeno-associated virus (AAV) variants expressing soluble FLT-1, a potent inhibitor of VEGF-mediated neovascularization and vascular permeability, to treat diabetic macular edema (DME). DME is an advanced form of diabetic… more
Company: Manus Biosynthesis, Inc. Agency/Program/Year/Phase: NSF / SBIR / 2012 / 1
Abstract: …, with a potential $3 billion global market. The use of this sweetener will improve taste profiles and expand adoption of low-calorie beverages, confectionaries, baked goods, dairy products, and so on, thus benefitting public health by reducing incidence of diabetes and… more
Company: VERISTRIDE, Inc. Agency/Program/Year/Phase: NSF / SBIR / 2012 / 1
Abstract: …e of where limbs are in space- that has been impaired by disability. Active cueing (in contrast to current reactive cueing methods) will provide a more proprioceptive feedback that will better enable persons with amputations due to systemic complications (e.g. diabetes) to… more
Company: Aptima, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … our goals are: 1) develop the STAMP prototype visualizations and system architecture; 2) evaluate the feasibility of STAMP in enabling education and shared medical decision-making. Long term goals for STAMP include its extension to other chronic conditions, e.g., diabetes… more
Company: LACELL, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …ypothesis that adipose-derived stromal/stem cell (ASC) therapy will accelerate and improve pressure ulcer healing in the elderly. Studies will be conducted in young (3-4 month) and old (24 month) C57Bl/6 male mice using leptin receptor deficient (db/db) obese diabetic mice (3-4… more
Company: AMICROBE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …tion to wound cavities prior to surgical closure could significantly reduce the number of superficial and deep incisional SSIs and organ-space SSIs. Amicrobe's hydrogel product may also help prevent infections in traumatic wounds and chronic wounds such as diabetic foot… more
Company: VALITOR, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION: In 2010, more than 875,000 Americans with diabetes were diagnosed with a lower extremity ulcer. Failed closure of these wounds results in more than 73,500 lower extremity amputations annually. Valitor, Inc. is developing protein-polymer therapeutics to overcome the… more
Company: MEDIKINE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Medikine will use SBIR funding to develop a novel therapeutic approach for treating diabetic nephropathy (DN) - a major life-threatening complication of diabetes, and the leading cause of chronic kidney disease and kidney… more
Company: BIODEL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … to continuously sensed glucose concentration data represents a modern attempt to mechanically simulate normal beta cell physiology and solve many of the problems associated with intensive insulin therapy today, including improving the quality of life for patients with diabetes… more
HELP FOR NARROW YOUR SEARCH
Search Options
Search for Either Criteria
Narrowing the Search Results
Search Options
There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.
Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.
Search for Either Criteria
When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.
Narrowing the Search Results
You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.